Key points for investors:
- Corporate separation and strategic refocus: Accendra Health has completed major separation activities from Owens & Minor and is now a stand-alone, pure-play home-based care company focused on growth and margin improvement.
- Large payor exit executed: The company substantially completed an exit from a large commercial capitated payor, selling patient-dedicated equipment for $82 million in cash (resulting in a $52 million book gain). Management says the transition preserved continuity of care and enabled rapid cost rationalization.
- Q1 financials and underlying performance: Reported Q1 2026 revenue declined 6.8% year-over-year; excluding the large payor impact, revenue would have been roughly +1%. Adjusted EBITDA was $58 million, in line with expectations. The company noted seasonal cash flow softness in Q1 with the back half of the year expected to be stronger (management expects at least 65% of adjusted EBITDA in Q3–Q4).
- Balance sheet optimization: Management announced a comprehensive transaction to extend maturities, materially reduce debt (estimated de-leveraging of up to ~$115 million), retire 2027 term loan A, issue new secured notes maturing in 2032/2033, and establish a new $300 million revolver due 2030. The weighted average life of debt would roughly double to ~5.5 years, removing 2027 maturity risk and improving liquidity.
- Interest expense and cash flow implications: Refinancing will lower near-term maturity risk but increase annual cash interest by ~ $40 million (about half of that impact hitting in H2 2026). Management expects free cash flow to be directed to debt reduction.
- Margin and operational improvements: Management highlights transformation to higher-margin business (management-cited gross margins near 50% and double-digit EBITDA margins vs. historical ~19% gross / ~4% EBITDA pre-divestiture) driven by centralization, standardization, automation, and cost reductions. Q1 included cost savings but also pressures from lower collection rates, product inflation, and higher health benefit expense.
- Growth initiatives: Sleep therapy is a strategic focus — the Sleep Journey and a newly formed Sleep Center of Excellence (pilot in 3 markets; rollout across network targeted by Q4) are producing higher revenue per order, lower attrition, and improved adherence. Other growth drivers include ostomy, urology, and home respiratory (category performance mixed; diabetes insulin pumps grew while CGM saw pricing/mix pressures).
- Outlook and priorities: Management reaffirmed 2026 revenue and adjusted EBITDA outlook, expects revenue and collections to improve through the year, continues emphasis on cost reduction and de-leveraging, and plans to use excess cash for debt paydown. Financing close was expected in mid–late June (per the call).
Sign In
Buy ACH
